Heat made AZ's FluMist ineffective against swine flu; Diamyd begins diabetes jab trial;

> FluMist maker AstraZeneca ($AZN) blames heat for its vaccine's ineffectiveness against swine flu. Report

> Diamyd Medical has dosed the first patient in its Type 1 diabetes vaccine study. Release

> ACIP has recommended Merck's ($MRK) Gardasil 9 for females ages 9 to 26 and males ages 9 to 21. Release

> In a Phase I study, Themis Bioscience's Chikungunya vaccine candidate raised concentrations of neutralizing antibodies in three dose cohorts after one immunization. Release

> Targovax has appointed Øystein Soug as its new CFO. Release

And Finally... The CDC says flu vaccines were only 18% effective this season. Report (reg. req.)

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.